Back to Authors

Algarin Perneth, Sandra L

Mayo Clinic

Mayo Clinic, Rochester, MN.

Citations 1

The Epidemiology of Young-Onset Barrett’s Esophagus in the United States
Vasireddy, Anila R. , Chandar, Apoorva K., Maravillas, Mart A., Perez, Jaime A., Perneth, Sandra L. Algarin, Leggett, Cadman L. , Katzka, David A. , Iyer, Prasad G. , Kamboj, Amrit K. , Vasireddy, Anila , Algarin Perneth, Sandra L, Kamboj, A K , Leggett, Cadman L , Chandar, Apoorva K., Maravillas, Mart Andrew , Kolb, Jennifer M. , Gaddam, Srinivas

Journal of Clinical Gastroenterology | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002394 Get It

Introduction: Young-onset esophageal adenocarcinoma (EAC) often presents at advanced stages and is associated with poor outcomes. We aimed to examine the epidemiology of young-onset Barrett’s esophagus (BE) using the TriNetX database. Methods: Young-onset BE patients (age 18 to younger than 50 y) with esophagogastroduodenoscopy (EGD) within 1 year before index BE diagnosis between 2014 and 2023 were included. Negative binomial regression was used to evaluate incident-time trends, and logistic regression to assess for independent predictors of young-onset BE. Results: BE diagnosis was present in 76,691 (3.3%) of 2,337,786 patients that underwent EGD, of which 14,120 (18%) had prevalent young-onset BE. BE dysplasia/EAC was present in 6% of young-onset patients at initial diagnosis. Conventional BE risk factors also predicted young-onset BE: GERD (OR=2.4), White race (OR=2.4), male sex (OR=2.2), smoking (OR=1.2), and obesity (OR=1.1). Each additional risk factor increased the probability of BE prevalence by 74% in young patients versus 54% in older patients. The prevalence of young-onset BE was 4.5% with GERD and ≥3 additional risk factors, and 2.3% when ≥3 risk factors were present. Discussion: Young-onset BE accounts for 18% of all BE cases, demonstrates a striking 6% rate of dysplasia/neoplasia at initial diagnosis, and has a prevalence of 4.5% in those with GERD and ≥3 risk factors. These findings suggest that young-onset BE is an important patient population that merits further study. Additional studies are necessary to study the cost-effectiveness of BE screening in younger patients with multiple risk factors.